MGCD265 is a novel multitargeted receptor tyrosine kinase (RTK) inhibitor that targets the mesenchymal epithelial transition (c-Met) and the vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2, and VEGFR3).
Molecular Weight:
517.6
Purity:
>98%
CAS Number:
[875337-44-3]
Formula:
C26H20FN5O2S2
Target:
c-Met
* VAT and and shipping costs not included. Errors and price changes excepted